We all know that many health tech names have struggled since going public. Insurtechs have been no different, as an incredibly difficult industry to crack for a new entrant. Today we’re diving into Oscar’s beginnings, its rise to public company, and then its fall into the abyss. Then, we’ll be taking a look at Oscar’s transformation and atonement for past transgressions, what’s on the horizon for the insurtech, and why, despite past slip-ups, Oscar could be poised for a major comeback.

UnitedHealth Group is once again coming for a major home health player. After Option Health Care in early May announced its intention to merge with Amedisys in a deal valued around $10 billion (Amedisys comprising around $3.6B of the combined enterprise at the time), Optum announced an offer to acquire Amedisys outright in an all-cash deal at $100 / share.

Today we’re taking a quick dive into some of the major stories that have emerged so far in healthcare in 2023, visualizing them, and understanding the bigger picture behind why things are happening.

The Fall of Babylon: I don’t relish in the failure of digital health companies – or any business, really. I’m generally a very positive person and hope/wish for the best, especially in healthcare. But firms like Babylon and Envision kinda had it coming for the ways the companies treated investors and patients.